Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
前日終値
$28.28
+$0.46 · +1.65%
時間外
$28.2667
−$0.0133 · -0.05%
10月9日 19:59 ET
日中の時刻はETです。市場データは遅延する場合があります。
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
日中レンジ
現在 $28.28
52週レンジ
現在 $28.28
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
78
割安
センチメント
48
まちまち
リスク
18
低リスク
モメンタム
36
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
日中レンジ
現在 $28.28
52週レンジ
現在 $28.28
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 625.79億 USD | 636.27億 USD | 595.53億 USD | 1003.3億 USD | 812.88億 USD |
| 売上原価 | 185.65億 USD | 217.81億 USD | 292.13億 USD | 382.4億 USD | 344.13億 USD |
| 粗利益 | 440.14億 USD | 418.46億 USD | 303.4億 USD | 620.9億 USD | 468.75億 USD |
| 研究開発 | 119.76億 USD | 107.38億 USD | 105.78億 USD | 114.26億 USD | 138.28億 USD |
| 販売・一般管理 | 133.46億 USD | 147.3億 USD | 144.7億 USD | 131.15億 USD | 122.54億 USD |
| 営業費用 | 285.77億 USD | 253.63億 USD | 250.48億 USD | 245.41億 USD | 260.82億 USD |
| 受取利息 | 6.03億 USD | 5.45億 USD | 16.24億 USD | 2.51億 USD | 3600万 USD |
| 支払利息 | 26.71億 USD | 30.91億 USD | 22.09億 USD | 12.38億 USD | 12.91億 USD |
| 減価償却費と償却費 | 65.92億 USD | 70.13億 USD | 62.9億 USD | 50.64億 USD | 51.91億 USD |
| 営業利益 | 154.37億 USD | 164.83億 USD | 52.92億 USD | 375.49億 USD | 207.93億 USD |
| 純利益 | 77.7億 USD | 80.2億 USD | 21.33億 USD | 313.65億 USD | 221.47億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$29.17
上昇余地(3.15%)AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。